Full text is available at the source.
Glucagon-like peptide-1 receptor agonists and muscle mass effects
How glucagon-like peptide-1 receptor activators affect muscle mass
AI simplified
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with significant weight loss and improved metabolic parameters.
- GLP-1 RAs may unintentionally reduce skeletal muscle mass.
- This reduction could exacerbate sarcopenic obesity, particularly in older or frail individuals.
- Current data suggests a need for awareness of these potential adverse effects.
- Strategies for mitigating muscle loss during GLP-1 RA therapy are discussed.
AI simplified